Wells Fargo
GSK icon

Wells Fargo’s GSK GSK Stock Holding History

Wells Fargo’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.6M Sell
1,405,498
-1,130,352
-45% -$61.3M 0.01% 734
2025
Q4 		$124M Sell
2,535,850
-308,137
-11% -$14.4M 0.02% 544
2025
Q3 		$123M Buy
2,843,987
+25,506
+0.9% +$996K 0.02% 535
2025
Q2 		$108M Buy
2,818,481
+1,385,761
+97% +$53M 0.02% 560
2025
Q1 		$55.5M Sell
1,432,720
-10,813
-0.7% -$396K 0.01% 767
2024
Q4 		$48.8M Sell
1,443,533
-130,796
-8% -$4.71M 0.01% 830
2024
Q3 		$64.4M Sell
1,574,329
-154,747
-9% -$6.33M 0.01% 699
2024
Q2 		$66.6M Sell
1,729,076
-177,644
-9% -$7.47M 0.02% 654
2024
Q1 		$81.7M Sell
1,906,720
-564,357
-23% -$23.3M 0.02% 566
2023
Q4 		$91.6M Sell
2,471,077
-9,177
-0.4% -$329K 0.02% 498
2023
Q3 		$89.9M Buy
2,480,254
+151,867
+7% +$5.39M 0.03% 463
2023
Q2 		$83M Buy
2,328,387
+16,081
+0.7% +$577K 0.02% 517
2023
Q1 		$82.3M Sell
2,312,306
-352,926
-13% -$12.3M 0.02% 503
2022
Q4 		$93.7M Sell
2,665,232
-59,923
-2% -$2M 0.03% 447
2022
Q3 		$80.2M Sell
2,725,155
-151,151
-5% -$5.73M 0.03% 473
2022
Q2 		$157M Buy
2,876,306
+120,696
+4% +$6.66M 0.05% 315
2022
Q1 		$150M Sell
2,755,610
-123,328
-4% -$6.7M 0.04% 366
2021
Q4 		$159M Buy
2,878,938
+56,142
+2% +$2.92M 0.04% 345
2021
Q3 		$135M Sell
2,822,796
-386,769
-12% -$19.4M 0.03% 523
2021
Q2 		$160M Sell
3,209,565
-115,025
-3% -$5.53M 0.04% 463
2021
Q1 		$148M Sell
3,324,590
-407,988
-11% -$18.5M 0.03% 493
2020
Q4 		$172M Sell
3,732,578
-1,215,511
-25% -$55.8M 0.04% 433
2020
Q3 		$233M Buy
4,948,089
+293,033
+6% +$14.7M 0.06% 290
2020
Q2 		$237M Sell
4,655,056
-93,726
-2% -$4.81M 0.07% 272
2020
Q1 		$225M Sell
4,748,782
-255,097
-5% -$13.6M 0.08% 244
2019
Q4 		$294M Sell
5,003,879
-90,591
-2% -$5.04M 0.08% 245
2019
Q3 		$272M Sell
5,094,470
-204,715
-4% -$10.5M 0.08% 249
2019
Q2 		$265M Buy
5,299,185
+118,046
+2% +$5.92M 0.08% 251
2019
Q1 		$271M Buy
5,181,139
+125,085
+2% +$6.25M 0.08% 235
2018
Q4 		$241M Sell
5,056,054
-241,293
-5% -$11.9M 0.08% 238
2018
Q3 		$266M Sell
5,297,347
-147,848
-3% -$7.51M 0.08% 266
2018
Q2 		$274M Sell
5,445,195
-140,698
-3% -$7.09M 0.08% 248
2018
Q1 		$273M Sell
5,585,893
-139,083
-2% -$6.48M 0.08% 255
2017
Q4 		$254M Sell
5,724,976
-4,274,730
-43% -$197M 0.07% 286
2017
Q3 		$507M Buy
9,999,706
+413,908
+4% +$21M 0.16% 143
2017
Q2 		$517M Buy
9,585,798
+261,917
+3% +$14M 0.17% 136
2017
Q1 		$491M Buy
9,323,881
+1,283,879
+16% +$65.1M 0.16% 139
2016
Q4 		$387M Sell
8,040,002
-151,673
-2% -$7.49M 0.14% 160
2016
Q3 		$442M Sell
8,191,675
-1,423,751
-15% -$78.1M 0.16% 140
2016
Q2 		$521M Buy
9,615,426
+427,949
+5% +$22.5M 0.2% 119
2016
Q1 		$466M Buy
9,187,477
+654,080
+8% +$32.6M 0.19% 124
2015
Q4 		$430M Sell
8,533,397
-59,769
-0.7% -$3.05M 0.17% 138
2015
Q3 		$413M Sell
8,593,166
-384,492
-4% -$20M 0.17% 129
2015
Q2 		$467M Buy
8,977,658
+302,523
+3% +$17M 0.18% 120
2015
Q1 		$500M Buy
8,675,135
+980,570
+13% +$56.2M 0.19% 120
2014
Q4 		$411M Buy
7,694,565
+467,323
+6% +$26.1M 0.16% 156
2014
Q3 		$415M Buy
7,227,242
+409,077
+6% +$25.1M 0.17% 147
2014
Q2 		$456M Buy
6,818,165
+42,810
+0.6% +$2.9M 0.19% 131
2014
Q1 		$453M Buy
6,775,355
+277,233
+4% +$18.7M 0.19% 132
2013
Q4 		$434M Buy
6,498,122
+248,981
+4% +$16.1M 0.19% 134
2013
Q3 		$392M Buy
6,249,141
+392,590
+7% +$25.3M 0.19% 139
2013
Q2 		$366M Buy
+5,856,551
New +$372M 0.19% 132

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo's GSK Position: Q1 2026 in Review

Wells Fargo reduced its GSK (GSK) stake by 45% in Q1 2026, selling an estimated $61.3M and leaving 1,405,498 shares worth $77.6M. The position accounts for 0.01% of the portfolio, ranked #734.

Wells Fargo first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $521M in Q2 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Wells Fargo held 1,405,498 shares of GSK worth $77.6M as of Q1 2026.
  • Wells Fargo sold 1,130,352 GSK shares in Q1 2026, an estimated $61.3M.
  • GSK made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #734 holding.
  • Wells Fargo first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's GSK position peaked at $521M in Q2 2016.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.